LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444 on ClinicalTrials.gov · last registry update 2026-10-14
An unusually large phase 3: 1,800 participants, more than double the 424 typical for the stage. Due to report 27 December 2031. Primary outcome, as filed: Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 14 October 2024 — 2 years so far. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 1,800
- Started
- 2024-10-14
- Primary completion
- 2031-12-27 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score
Conditions studied
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.